Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment

Exp Dermatol. 2010 Aug;19(8):754-6. doi: 10.1111/j.1600-0625.2010.01089.x.

Abstract

To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction >50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-alpha) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis.

Publication types

  • Letter

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • Biomarkers / metabolism
  • Biopsy
  • CD3 Complex / metabolism
  • Etanercept
  • Female
  • Humans
  • Immunity, Innate*
  • Immunoglobulin G / therapeutic use*
  • Lectins, C-Type / metabolism
  • Male
  • Membrane Glycoproteins / metabolism
  • Middle Aged
  • NK Cell Lectin-Like Receptor Subfamily B / metabolism
  • Pancreatic Elastase / metabolism
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Psoriasis / pathology*
  • Receptors, Immunologic / metabolism
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Skin / metabolism
  • Skin / pathology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Biomarkers
  • CD3 Complex
  • CD68 antigen, human
  • CLEC4C protein, human
  • Immunoglobulin G
  • Lectins, C-Type
  • Membrane Glycoproteins
  • NK Cell Lectin-Like Receptor Subfamily B
  • Receptors, Immunologic
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Pancreatic Elastase
  • Etanercept